<DOC>
	<DOCNO>NCT00466687</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving erlotinib together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give erlotinib together bevacizumab work treat patient stage IV melanoma .</brief_summary>
	<brief_title>Erlotinib Bevacizumab Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall response rate , response duration , frequency progression-free survival 6 month patient stage IV melanoma treat erlotinib hydrochloride bevacizumab . - Determine objective response patient treat regimen . Secondary - Determine overall safety tolerability regimen patient . - Evaluate tissue block EGFR monoclonal antibody H11 ( DAKO ) fluorescence situ hybridization ( FISH ) 7p12-specific probe-overexpression amplification patient treat regimen . OUTLINE : This multicenter study . Patients receive oral erlotinib hydrochloride daily day 1-28 bevacizumab IV 30-90 minute day 1 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo tissue collection analyze EGFR monoclonal antibody H11 ( DAKO ) fluorescence situ hybridization ( FISH ) 7p12-specific probe-overexpression amplification . Biological marker AKT , MAPK , p27 , p21 , CD13 , CD34 , factor VIII also measure . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Measurable Stage IV melanoma Easter Cooperative Oncology Group ( ECOG ) Performance Status must 01 Good organ function demonstrate , Creatinine &lt; 2.mg/dl , AST ALT &lt; 5 time upper limit normal subject document liver metastasis ; &lt; 2.5 time upper limit normal ( ULN ) subject without evidence liver metastasis , bilirubin &lt; 2.0mg/dl , , absolute neutrophil count ( ANC ) &gt; 1500/ul , platelet &gt; 75k/ul , hemoglobin ( Hgb ) &gt; 9 ( may transfuse obtain ) Prior therapy : adjuvant interferon ( IFN ) allow ; one prior regimen advance stage IV disease Patients must life expectancy &gt; 3 month Patients brain metastasis eligible fulfill follow : resect stereotactic treatment minimum 3 month previously active CNS disease since ; brain metastasis treat great 6 month ago without evidence progression hemorrhage , &lt; 1cm size per lesion ( 3 lesion ) , steroids Patients may receive agent , either investigational market , act either EGFr inhibition antiangiogenesis mechanism . Other epidermal growth factor receptor ( EGFR ) inhibitor include ( limited ) : Iressa , erbitux , CI1033 . Angiogenesis inhibitor include ( limited ) : SU5416 , SU6668 , SU 0122348 , CP547632 , VEGF Trap , antiintegrin αVβ3 . Recovered toxicity major surgery ( 4 wks ) , chemotherapy biologic therapy ( 4 wks ) , and/or radiation therapy ( 2 wks ) No active malignancy within 12 month No active systemic infection Over age 18 year sign IRB approve informed consent Subjects meet follow criterion ( 3.2.2—3.2.16 ) ineligible study entry Compromised renal hepatic function define Creatinine &gt; 2.0mg/dl , aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 5 time upper limit normal subject document liver metastasis ; &gt; 2.5 time upper limit normal ( ULN ) subject without evidence liver metastasis Patient may part investigational study internationalize normal ratio ( INR ) &gt; 1.5 Patients PEG Gtube ineligible . Major surgical procedure , open biopsy ; significant traumatic injury within 28 day , anticipation need major surgical procedure course study Any nonhealing wound , ulcer , bone fracture . Any clinical evidence history bleed diathesis coagulopathy . Patients history deep vein thrombosis thromboembolic disease within past 6 month . History acute myocardial infarction within 6 month . In addition , patient ineligible clinically significant cardiovascular disease ( ( e.g. , uncontrolled hypertension [ blood pressure &gt; 160/110 mmHg medication ] , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac dysrhythmia require medication , peripheral vascular disease ( Grade II great ) Patients &gt; 1+ proteinuria 24hour urine collection ; protein . Patients ≥ 1gm protein/24 hr exclude If child bearing age must pregnant nursing use method prevent pregnancy History evidence upon physical examination central nervous system ( CNS ) disease ( e.g. , primary brain tumor , seizures control standard medical therapy , history stroke ) Inability comply study and/or followup procedure History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>